Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features

Charles M. Rudin, John T. Poirier, Neil N. Senzer, Joseph Stephenson, David Loesch, Kevin D. Burroughs, P. Seshidhar Reddy, Christine Hann, Paul L. Hallenbeck

Research output: Contribution to journalArticle

Abstract

Purpose: Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer cell types, including small cell lung cancer. We conducted a first-in-human, first-in-class phase I clinical trial of this agent in patients with cancers with neuroendocrine features, including small cell lung cancer. Experimental Design: Clinical evaluation of single intravenous doses in patients with cancers with neuroendocrine features was performed across five log-increments from 107 to 1011 vp/kg. Toxicity, viral titers and clearance, neutralizing antibody development, and tumor response were assessed. Results: A total of 30 patients were treated with SVV-001, including six with small cell carcinoma at the lowest dose of 107 vp/kg. SVV-001 was well tolerated, with no dose-limiting toxicities observed in any dose cohort. Viral clearance was documented in all subjects and correlated temporally with development of antiviral antibodies. Evidence of in vivo intratumoral viral replication was observed among patients with small cell carcinoma, with peak viral titers estimated to be >103-fold higher than the administered dose. One patient with previously progressive chemorefractory small cell lung cancer remained progression-free for 10 months after SVV-001 administration, and is alive over 3 years after treatment. Conclusions: Intravenous SVV-001 administration in patients is well tolerated at doses up to 1011 vp/kg, with predictable viral clearance kinetics, intratumoral viral replication, and evidence of antitumor activity in patients with small cell lung cancer. Phase II clinical evaluation in small cell lung cancer is warranted, and has been initiated.

Original languageEnglish (US)
Pages (from-to)888-895
Number of pages8
JournalClinical Cancer Research
Volume17
Issue number4
DOIs
StatePublished - Feb 15 2011

Fingerprint

Picornaviridae
Neuroendocrine Tumors
Small Cell Lung Carcinoma
Viruses
Small Cell Carcinoma
Neoplasms
Neuroendocrine Cells
Clinical Trials, Phase I
Tropism
Proxy
Neutralizing Antibodies
Antiviral Agents
Clinical Studies
Research Design
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. / Rudin, Charles M.; Poirier, John T.; Senzer, Neil N.; Stephenson, Joseph; Loesch, David; Burroughs, Kevin D.; Reddy, P. Seshidhar; Hann, Christine; Hallenbeck, Paul L.

In: Clinical Cancer Research, Vol. 17, No. 4, 15.02.2011, p. 888-895.

Research output: Contribution to journalArticle

Rudin, Charles M. ; Poirier, John T. ; Senzer, Neil N. ; Stephenson, Joseph ; Loesch, David ; Burroughs, Kevin D. ; Reddy, P. Seshidhar ; Hann, Christine ; Hallenbeck, Paul L. / Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 4. pp. 888-895.
@article{1414534c05a5497fbff8c22ee26d08f0,
title = "Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features",
abstract = "Purpose: Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer cell types, including small cell lung cancer. We conducted a first-in-human, first-in-class phase I clinical trial of this agent in patients with cancers with neuroendocrine features, including small cell lung cancer. Experimental Design: Clinical evaluation of single intravenous doses in patients with cancers with neuroendocrine features was performed across five log-increments from 107 to 1011 vp/kg. Toxicity, viral titers and clearance, neutralizing antibody development, and tumor response were assessed. Results: A total of 30 patients were treated with SVV-001, including six with small cell carcinoma at the lowest dose of 107 vp/kg. SVV-001 was well tolerated, with no dose-limiting toxicities observed in any dose cohort. Viral clearance was documented in all subjects and correlated temporally with development of antiviral antibodies. Evidence of in vivo intratumoral viral replication was observed among patients with small cell carcinoma, with peak viral titers estimated to be >103-fold higher than the administered dose. One patient with previously progressive chemorefractory small cell lung cancer remained progression-free for 10 months after SVV-001 administration, and is alive over 3 years after treatment. Conclusions: Intravenous SVV-001 administration in patients is well tolerated at doses up to 1011 vp/kg, with predictable viral clearance kinetics, intratumoral viral replication, and evidence of antitumor activity in patients with small cell lung cancer. Phase II clinical evaluation in small cell lung cancer is warranted, and has been initiated.",
author = "Rudin, {Charles M.} and Poirier, {John T.} and Senzer, {Neil N.} and Joseph Stephenson and David Loesch and Burroughs, {Kevin D.} and Reddy, {P. Seshidhar} and Christine Hann and Hallenbeck, {Paul L.}",
year = "2011",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-10-1706",
language = "English (US)",
volume = "17",
pages = "888--895",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features

AU - Rudin, Charles M.

AU - Poirier, John T.

AU - Senzer, Neil N.

AU - Stephenson, Joseph

AU - Loesch, David

AU - Burroughs, Kevin D.

AU - Reddy, P. Seshidhar

AU - Hann, Christine

AU - Hallenbeck, Paul L.

PY - 2011/2/15

Y1 - 2011/2/15

N2 - Purpose: Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer cell types, including small cell lung cancer. We conducted a first-in-human, first-in-class phase I clinical trial of this agent in patients with cancers with neuroendocrine features, including small cell lung cancer. Experimental Design: Clinical evaluation of single intravenous doses in patients with cancers with neuroendocrine features was performed across five log-increments from 107 to 1011 vp/kg. Toxicity, viral titers and clearance, neutralizing antibody development, and tumor response were assessed. Results: A total of 30 patients were treated with SVV-001, including six with small cell carcinoma at the lowest dose of 107 vp/kg. SVV-001 was well tolerated, with no dose-limiting toxicities observed in any dose cohort. Viral clearance was documented in all subjects and correlated temporally with development of antiviral antibodies. Evidence of in vivo intratumoral viral replication was observed among patients with small cell carcinoma, with peak viral titers estimated to be >103-fold higher than the administered dose. One patient with previously progressive chemorefractory small cell lung cancer remained progression-free for 10 months after SVV-001 administration, and is alive over 3 years after treatment. Conclusions: Intravenous SVV-001 administration in patients is well tolerated at doses up to 1011 vp/kg, with predictable viral clearance kinetics, intratumoral viral replication, and evidence of antitumor activity in patients with small cell lung cancer. Phase II clinical evaluation in small cell lung cancer is warranted, and has been initiated.

AB - Purpose: Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer cell types, including small cell lung cancer. We conducted a first-in-human, first-in-class phase I clinical trial of this agent in patients with cancers with neuroendocrine features, including small cell lung cancer. Experimental Design: Clinical evaluation of single intravenous doses in patients with cancers with neuroendocrine features was performed across five log-increments from 107 to 1011 vp/kg. Toxicity, viral titers and clearance, neutralizing antibody development, and tumor response were assessed. Results: A total of 30 patients were treated with SVV-001, including six with small cell carcinoma at the lowest dose of 107 vp/kg. SVV-001 was well tolerated, with no dose-limiting toxicities observed in any dose cohort. Viral clearance was documented in all subjects and correlated temporally with development of antiviral antibodies. Evidence of in vivo intratumoral viral replication was observed among patients with small cell carcinoma, with peak viral titers estimated to be >103-fold higher than the administered dose. One patient with previously progressive chemorefractory small cell lung cancer remained progression-free for 10 months after SVV-001 administration, and is alive over 3 years after treatment. Conclusions: Intravenous SVV-001 administration in patients is well tolerated at doses up to 1011 vp/kg, with predictable viral clearance kinetics, intratumoral viral replication, and evidence of antitumor activity in patients with small cell lung cancer. Phase II clinical evaluation in small cell lung cancer is warranted, and has been initiated.

UR - http://www.scopus.com/inward/record.url?scp=79951821209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951821209&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-1706

DO - 10.1158/1078-0432.CCR-10-1706

M3 - Article

C2 - 21304001

AN - SCOPUS:79951821209

VL - 17

SP - 888

EP - 895

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -